Investigation of biomarkers to predict immune-related adverse events in patients with non-small cell lung cancer
Not Applicable
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000047162
- Lead Sponsor
- Kobe University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 114
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients with active double cancer (simultaneous double cancer and metachronous double cancer with no disease period within 3 years). 2. Patients with ILD complications prior to treatment (Intestinal Lung Abnormality (ILA) is acceptable). 3. Patients with autoimmune disease. 4. Patients taking 10 mg or more of prednisolone. 5. Patients who the principal investigator deems inappropriate for this study.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Onset of drug-induced interstitial lung disease
- Secondary Outcome Measures
Name Time Method Onset of immune-related adverse events
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular biomarkers are being investigated for predicting immune-related adverse events in NSCLC patients in JPRN-UMIN000047162?
How do the biomarkers identified in JPRN-UMIN000047162 compare to existing predictors of irAEs in immunotherapy-treated NSCLC?
What immune checkpoint pathways are associated with the biomarkers studied in this Kobe University NSCLC observational trial?
Are there specific genetic or proteomic profiles in NSCLC that correlate with immune-related adverse event risk as explored in JPRN-UMIN000047162?
How might the findings from JPRN-UMIN000047162 influence patient selection for PD-1/PD-L1 inhibitor therapies in NSCLC?